Ergotamine D-tartrate

CAS: 379-79-3

Ref. 3D-FE30656

Información del producto

• Nombre: Ergotamine D-tartrate
• Sinónimos: (5'Alpha)-5'-Benzyl-12'-Hydroxy-2'-Methyl-3',6',18-Trioxoergotaman 2,3-Dihydroxybutanedioate (1:1), (5'alpha)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-Ergotaman-3',6',18-trione, [R-(R*,R*)]-2,3-dihydroxybutanediate (2:1) (salt), Ergam, Ergate, Ergomar, Ergostat, Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (2:1) (salt), Ergotaman-3′,6′,18-trione, 12′-hydroxy-2′-methyl-5′-(phenylmethyl)-, (5α)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1), Ergotaman-3′,6′,18-trione, 12′-hydroxy-2′-methyl-5′-(phenylmethyl)-, (5′α)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt), Ergotaman-3′,6′,18-trione, 12′-hydroxy-2′-methyl-5′-(phenylmethyl)-, (5′α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (2:1) (salt), Ergotamine Bitartrate, Ergotamine, tartrate (2:1) (salt), Ergotartrat, Etin, Exmigra, Femergin, Gotamine, Gotamine tartrate, Gynergen, Gynergin, Lingraine, Lingran, Medihaler-ergotamine, NSC 41869, Neo-Ergotin, Rigetamin, Secagyn, Secupan, Ergotamine tartrate

Descripción

Ergotamine D-tartrate is a drug that belongs to the group of nonsteroidal anti-inflammatory drugs. It is used in the treatment of migraine and other headaches. Ergotamine D-tartrate inhibits the production of nitric oxide, which has been shown to be involved in the process of angiogenesis. This drug also has long-term efficacy for headaches and migraines, as well as an anti-migraine effect. Ergotamine D-tartrate binds to specific receptors on neurons called alpha2 adrenergic receptors, which are located on blood vessels in the brain and have been implicated in migraine pathophysiology. These receptors are not present on vessels elsewhere in the body, which makes ergotamine a more selective drug for migraine than other nonsteroidal anti-inflammatory drugs.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 1,313.44 g/mol
• Fórmula: (C₃₃H₃₅N₅O₅)₂•C₄H₆O₆
• Pureza: Min. 95%